Post-Hoc Live

Each year, the Endpoints newsroom places bets on the 11 private biotech companies that we think are the most promising, the most cutting-edge — and would leave the biggest crater behind if things go belly-up. Wednesday on Post-Hoc Live, we’ll share a behind-the-scenes look at how we pick the Endpoints 11, tease what types of companies we focused on this year, and look back at what’s happened to th...

John Maraganore and Clive Meanwell are teaming up again. The two biotech luminaries are coming out of stealth today as co-CEOs of Corsera Health, and have plans to create a two-RNAi drug for cardiovascular disease prevention. They’re joining Post-Hoc Live today to talk about why they’re betting their own money on the venture, their approach to starting companies, and what they think is coming next...

mRNA-based Covid-19 vaccines were a signature accomplishment under the first Trump administration. But now, RFK Jr. is in charge at HHS, and he’s cutting contracts with mRNA vaccine makers. We’re joined today by Brett Giroir, the assistant secretary for health at HHS under the first Trump administration, to talk about the impact of MAHA’s vaccine agenda — and what the changes mean for the future o...

After three weeks of corporate earnings reports, we’ve got a roundup of news and analysis taking in all of the biotech and pharma companies that gave updates. We’ll dig into what big pharma companies are saying about the Trump administration’s tariff, pricing and regulatory moves, how companies are talking about China and what we learned about closely watched results from a few key companies like...

Earlier this month, Curie. Bio CEO Zach Weinberg joined Post-Hoc Live to give his take on why he thinks investors should stay away from Chinese biotechs. Today, we’re joined by Cui Cui, the head of Asia healthcare research at Jefferies, to get her perspective on the China biotech boom, and why US pharma companies keep turning to China for their deals (and not to US startups).

In the last two weeks, Sarepta has been threatened by the FDA with having its drug pulled, refused to do so, then capitulated, and then won a reversal by the regulator. We'll talk with R.W. Baird analyst Brian Skorney, who has followed the company's ups and downs for years, and what this latest twist tells us about the company's future, how this FDA is operating, and the power of patie...

Things don’t look good for Sarepta. After reports of a third patient death on Thursday — this one in a clinical trial — which wasn’t disclosed by the company in its corporate update, an HHS official told Endpoints that the FDA would ask the company to stop shipping its Duchenne muscular dystrophy treatment Elevidys. Stock is down. Leadership is under fire for not being transparent about patient de...

Are drugs in space for real this time? Varda Space Industries, which just announced they had raised $137 million to start industrializing bio-processing in low-earth orbit, certainly thinks so. Endpoints Executive Editor Drew Armstrong and Senior Science Correspondent Ryan Cross are more skeptical — so Varda’s Chief Science Officer Adrian Radocea is joining Post-Hoc Live to try and convince them t...

Biopharma companies are increasingly turning to China to find new molecules, and looking to Chinese companies for licensing deals. Some investors are leaning in — but others, like Curie. Bio CEO Zach Weinberg, think they should stay away. This week, Weinberg joins Post-Hoc Live to help us to take stock of the landscape. Be sure to check out our coverage before you tune in: https://endpoints.news/u...

It’s a busy week in Washington. RFK Jr. faced the House Energy and Commerce Subcommittee on Health. The newly reconstructed ACIP will meet for the first time. And Susan Monarez will go before the Senate Health, Education, Labor, and Pensions Committee for her confirmation hearing to lead the Centers for Disease Control and Prevention. We’ll go live after the final ACIP votes on Thursday, June 26 t...

We’re coming to you live from Boston, where Endpoints reporters have spent the past few days at BIO 2025 talking with industry leaders. The mood in the industry has been bleak — how is that playing out on the ground?

Today, Drew Armstrong will be joined by senior biopharma correspondent Andrew Dunn and Abhi Mahajan, a machine learning expert who writes about the intersection of ML and biology at Owl Posting. They'll talk about how AI is evolving, what it’ll mean if (or when) it improves past our ability to understand it, and how that will affect drug development.

HHS Secretary Robert F. Kennedy Jr. fired the CDC's vaccine advisory board known as ACIP, which for years has played a key role in setting US vaccination policy on everything from measles to flu to Covid-19. To assess the fallout, we're speaking with former CDC Director Mandy Cohen, who led the agency from 2023 to 2025.

For the next Post-Hoc live, I'll be joined by Endpoints Founding Editor John Carroll to talk about his twice-a-year sentiment survey of biotech and pharma execs. The results aren't pretty, and John will put them into perspective against more than half a decade of checking the industry's pulse. We'll also be joined by Senior Reporter Kyle LaHucik, who covers public and private deals...

Today, Drew Armstrong is joined by Nick Shipley, the former top lobbyist for the biotech industry, to break down President Trump's "most favored nation" executive order on drug pricing. We’ll talk about what the White House wants, how it could implement those plans, and how the industry and investors are reacting.

Today, we'll be talking about the news that Vinay Prasad will join FDA as the next director of the Center for Biologics and Research. We'll talk about his past critiques of the agency, his disagreements with former director Peter Marks, and how is tenure might affect vaccine policy, gene therapies, and rare disease companies. I’ll be joined by our senior editor Zach Brennan, who has known...

We recorded this on April 30, four weeks after Trump’s Liberation Day, when he announced broad tariffs on just about every country on earth, set off chaos in the stock and bond markets, walked some of those tariffs back, and in general upset the world economic order.  If you’ve been reading the news, you know all of that. And if you work in the drug industry, then you’ve been watching and waiting...

This semi-regular series is an extension of out analysis newsletter Post-Hoc. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We wanted to bring some of that analysis that happens behind the scenes directly to you. We fire Post-Hoc live up in response to major news, at the end of news-y weeks, and to talk to experts about tre...